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Abstract
We consider the validation  of prognostic diagnostic tests that predict two prognostic 
subgroups (high-risk vs low-risk) for a given disease or treatment. When comparing 
survival curves between two prognostic subgroups the possibility of misclassification 
arises, i.e. a patient predicted as high-risk might be de facto low-risk and vice versa. 
This is a fundamental difference from comparing survival curves between two 
populations (e.g. control vs treatment in RCT), where there is not an option of 
misclassification between members of populations. We show that there is a 
relationship between prognostic subgroups’ survival estimates at a time point and 
positive and negative predictive values in the classification settings. Consequently, the
prevalence needs to be taken into account when validating the survival of prognostic 
subgroups at a time point. Our findings question current methods of comparing 
survival curves between prognostic subgroups in the validation set because they do 
not take into account the survival rates of the population.
Introduction
The goal of personalised medicine is to apply treatments only to individuals who will 
benefit from them. This presumes that we have available clinical and genetic 
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information about the patients as well as statistical methodology to identify a 
subgroup which benefits from a treatment. From the statistical point of view, the 
future of personalised medicine depends on how well we can separate a subgroup of 
patients that benefits from a treatment. Our starting point is a single survival 
population. Our goal is to use all available data about the patients to build a predictive
model in order to find two sub-groups, one with better and the other with worse 
survival prognoses. However, in order to achieve the goal we need to have a set of 
well-defined statistics which measure, as accurately as possible, the differences 
between the subgroups' survival prognoses.
A common procedure when validating prognostic separation is to perform the same 
actions as when comparing two survival populations, i.e. to estimate survivor 
functions for each prognostic group with Kaplan-Meier (KM) survival curve [1], to 
calculate hazard ratio (HR)  [2] and to compare the curves with the log-rank test [3]. 
Royston and Altman [4] say the following on this subject: “Kaplan-Meier survival 
curves for risk groups provide informal evidence of discrimination. The more widely 
separated are the curves, the better is the discrimination. A Kaplan-Meier graph for 
both datasets allows a visual comparison of discrimination between datasets. We 
strongly recommend producing such plots.”. In Fig. 1 we show an example of KM 
survival curves for two prognostic subgroups as well as calculated HR and the p-value
for the log-rank test. 
Our thesis is that current statistical methods for comparing survival curves between 
two prognostic subgroups may be misleading because they do not take into account 
the survival rates of the population.
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Methods
It is very important that we clearly define the terms we use. The survival population is
a homogeneous population of individuals each having a “failure time”. Let T be a 
non-negative random variable representing the “failure time” of an individual from 
the survival population. The survivor function S(t) = P({T>t}) is the probability that T 
exceeds the value t [5][6]. In practice we usually do not know the survivor functions, 
but we are able to estimate them. We use the term survival curve when we refer to an 
estimate of a survivor function. The population survival rate at time To S(To) is the 
proportion of the population with “failure time” after To. 
We use a predictive model to separate a survival population into two prognostic 
subgroups: high-risk and low-risk. In practice the prognostic sub-groups are usually 
created after dichotomising a prognostic index, a numerical output of a prognostic 
model [4]. We are interested in the process of external validation, which means 
assessing a model of prognostic separation already developed when applied to an 
independent dataset [4]. We refer to a dataset used in external validation as the 
validation dataset.  In order to explain our point we will suppose that there is no 
censored data in our validation dataset, i.e. we know the exact failure time for each 
subject.
Estimating the survival of high-risk and low-risk patients at time To
To start with, we are interested in estimating the survival of high-risk and low-risk 
patients at time To, i.e. SHIGH-RISK(To) and SLOW-RISK(To). In the absence of censoring, 
we can estimate it for each prognostic subgroup as a ratio of the number of patients 
who had an event after To over the size of the subgroup in the validation dataset. 
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Therefore, if we categorise patients with an event before or equal to To as positive, 
and with an event after To as negative, then we can create a contingency table as in 
Table 1. In that case SHIGH-RISK(To)=c/(c+d) and SLOW-RISK(To)=a/(a+b) and we refer to 
them as naive estimates. 
It is important to understand that when we apply prognostic separation of a single 
population mistakes will occur. An individual who is in reality high-risk may be 
wrongly predicted as low-risk and vice versa. With a prognostic separation we have 
the possibility of misclassifying individuals, and we can introduce the following 
convention. Patients who had an event after To and who are predicted as low-risk 
would be true negatives (TN), while those who are predicted as high-risk would be 
false negatives (FN). Similarly, patients with an event before or equal to To who are 
predicted as high-risk would be true positives (TP), while those who are predicted  as 
low-risk would be false positives(FP). Using this simple diagnostic test we can 
calculate sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) [7][8]. We can estimate the sensitivity and specificity from a 
validation set, but without the knowledge of prevalence we are unable to estimate 
PPV or NPV [8]. The prevalence is the proportion of positive patients in the 
population, also known as the prior probability of being positive. It is a measure 
independent of the validation dataset.  If, however, we know the prevalence then the 
predictive values would be estimated with the following equations [8]:
(Eq1)
(Eq2)
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In our case then SHIGH-RISK(To) and SLOW-RISK(To) would be estimates of proportions of 
negative samples in the high-risk and low-risk prognostic subgroups, i.e.
 SHIGH-RISK(To) = (1 – PPV)                                           (Eq3)
SLOW-RISK(To) = NPV                                                   (Eq4)
And here we have a problem. Their estimates depend on the prevalence.  In our case 
prevalence is the proportion of patients in the population who had an event before or 
equal to time To, i.e. 
prevalence = 1 – S(To)                                            (Eq5)
Therefore, we cannot estimate SHIGH-RISK (To) or SLOW-RISK (To) without the knowledge 
of the population survival rate at To. Consequently, we cannot use the naive estimates 
c/(c+d) and a/(a+b) as our estimates for SHIGH-RISK (To) and SLOW-RISK (To).
In survival settings the most common method of estimating survival at time To is to 
use Kaplan-Meier product-estimator [1]. However, in the absence of censoring, as we 
will show in our simulation example, the KM estimates for both prognostic subgroups
at To are identical to the naive estimates. We thus conclude that in the absence of 
censoring we cannot use KM to estimate the survival of prognostic subgroups at To 
because it does not take into account the population survival rate at T=To. 
Furthermore, as this holds for any time-point To, we also conclude that in the absence 
of censoring we cannot use KM curves to compare the survival of two prognostic 
subgroups. 
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Comparing survival curves of two prognostic subgroups
We argue that our conclusion holds when a validation dataset is with censored data 
and when we use estimates of survival curve other than KM [5][10]. The fundamental
question here is what we are trying to estimate, and not how. In the case of prognostic 
subgroups, the possibility of misclassification exists and, as we have shown, estimates
of survival for each prognostic subgroup at a time-point are related to predictive 
values. This means that for each time-point we have to take into account the 
population survival rate at the time-point in order to estimate the survival of 
prognostic subgroups. Therefore, regardless of having censored data or not, and 
regardless of applying KM to estimate survival curves or not, we need to take into 
account the population survival rates in order to estimate the survival of the 
prognostic sub-groups. Consequently, comparing survival curves between two 
prognostic subgroups without taking into account the population survival rates may 
produce incorrect estimates.
How to estimate the survival of high-risk and low-risk patients at time To in 
practice?
In order to estimate the survival of high-risk and low-risk patients at time To we need 
to know the population survival rate at To, i.e. S(To). Furthermore, the survivalROC 
R package [9][11] provides a way of estimating sensitivity and specificity at To using 
survival data. Therefore, by knowing prevalence (Eq5), and with estimated sensitivity 
and specificity at To, we can then apply equations (Eq1)-(Eq4) to calculate SHIGH-RISK 
(To) and SLOW-RISK (To).
- 6 -
Difference in the survival of high-risk and low-risk patients at time To
We now examine whether the difference between estimates of the survival of high-
risk and low-risk patients at time To depends on the population survival rate at To. In 
the equation Eq6 we show that it clearly does.  
SLOW-RISK (To) - SHIGH_RISK(To)  = PPV + NPV – 1
SLOW-RISK (To) - SHIGH_RISK(To)  =                          
         (Eq6)
However, it is not clear from the equation how the population survival rate affects the 
difference and to what extent. In Fig. 2 we show the difference between SLOW-RISK (To) 
and SHIGH-RISK (To) as the function of the population survival rate where specificity and 
sensitivity are constants. The function is constant, i.e. equal to zero, when 
spec+sens=1. However, when spec+sens>1 then the function has a single maximum 
value and as the survival rate approaches 0 or 1 the difference is closer to zero. 
Results 
We created an example with simulated survival dataset without any censored data. 
Our intention is to analyse the effect of various population survival rates on our 
estimates of the 5-year survival of high-risk and low-risk patients. Later we use the 
same dataset and randomly transform 30% of it into censored data. We then apply the 
same analysis to it.
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Simulated example 
We generated samples of 400 high-risk and 400 low-risk patients with different 
exponential survival distributions and without any censored data. KM graphs for both 
prognostic subgroups are shown in Fig.3. We are interested in estimating 5-year 
survival for both prognostic subgroups . Using the KM product estimator we calculate
that SHIGH-RISK (5 years)=0.205 while SLOW-RISK (5 years)=0.3575. Similarly, if we 
categorise patients with an event before or equal to 5 years as positive, and with an 
event after 5 years as negative, then we would have a confusion matrix as shown in 
Table 2 with sensitivity=0.553, specificity=0.636. It is worth noting that in the 
validation dataset the 5-year survival rate is 28.125%. Furthermore, as expected, KM 
estimates are identical to the naive estimates,  SHIGH-RISK (5 years)=82/400=0.205  SLOW-
RISK (5 years)=143/400=0.3575
What happens if the 5-year population survival rate is different from 28.125%? In 
Table 3 we show estimates of SHIGH-RISK (5 years) and SLOW-RISK (5 years) calculated with
equations (Eq1)-(Eq5) for various 5-year population survival rates. KM estimates for  
SHIGH-RISK (5 years) and SLOW-RISK (5 years) are also presented. Various estimates for 
SHIGH-RISK (5 years) and SLOW-RISK (5 years) show their dependency on the 5-year 
population survival rate. Furthermore, it confirms that if the 5-year survival rate in the
validation dataset is different from the 5-year population survival rate then the KM 
estimates would be misleading.
Censored data 
We modified the simulated dataset so that it contains censored data. We randomly 
selected 30% of patients in both prognostic subgroups to be censored. For each 
- 8 -
censored patient we assigned its last known survival time to be a random number 
between 0 and its actual “failure” time. KM graphs for both prognostic subgroups are 
shown in Fig.4. Using the KM product estimator we calculated that SHIGH-RISK (5 
years)=0.2463 while SLOW-RISK (5 years)=0.4238. We calculated specificity and 
sensitivity at 5 years (5-year-spec=0.6374, 5-year-sens=0.5706) with the survivalROC
R package. Similar as in Table 3, we show in Table 4 estimates of SHIGH-RISK (5 years) 
and SLOW-RISK (5 years) calculated with equations (Eq1)-(Eq5) for various 5-year 
population survival rates, as well as KM estimates. Again we see different estimates 
for SHIGH-RISK (5 years) and SLOW-RISK (5 years) depending on the 5-year population 
survival rate. 
Discussion
In practice we have never worked with a validation dataset that does not have 
censored data. Consequently, we have never had a chance to use naive estimates nor 
to create a confusion matrix for a particular time-point as described above. The most 
common method for estimating survival with censored data is to use KM estimates. 
However, even though with censored data we cannot clearly show the close 
relationship between KM and naive estimates, we argue that if the relationships exist 
in the non-censored case then they must exist in the censored.
In theory an external validation dataset ought to be representative of the population, 
but in practice it seldom is, or it is difficult to prove that it is. If we want to compare 
survival curves of prognostic subgroups, we have shown that the external validation 
dataset ought to have the same survival rates as the population for all time-points. 
Furthermore, we have shown that without prior knowledge of the population survival 
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rates we cannot estimate survival curves of prognostic sub-groups. As a consequence, 
Kaplan-Meier survival curves for prognostic sub-groups, as well as their hazard ratio 
and the p-value for the log-rank test, may be wrong. 
We disagree with the strong recommendation by Royston and Altman [4] to produce a
plot with KM survival curves for both prognostic subgroups as a visual comparison of
discrimination between them. We think the plot might be an inaccurate representation 
of the discrimination between prognostic subgroups. In Table 5 we show the 
differences in the 5-year survival between prognostic subgroups for various 
combinations of specificity, sensitivity, 5-year population survival rate and 5-year 
survival rate in the validation dataset. The “5-year survival difference” is calculated 
taking into account the 5-year population survival rate, while the “naive 5-year 
survival difference” is based on the 5-year survival rate in the validation dataset. It 
shows that we can overestimate as well as underestimate the difference in the 5-year 
survival between prognostic subgroups if the 5-year population survival rate is not 
taken into account.
In our opinion, the way forward is not to compare survival curves of prognostic 
subgroups but to report their survival at specific time-points. They would be  
calculated using the population survival rate, specificity and sensitivity (Eq5). If no 
historical data exist from which one could generate a population survival rate, then 
one would report specificity and sensitivity at specific time-points.
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Conclusion
We have shown that we are not able to estimate the survival of prognostic subgroups 
without the knowledge of population survival rates. We have shown that the 
relationship is the same as between negative and positive predictive values and 
prevalence.
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Figure 1  - An example of Kaplan-Meier survival curves for two prognostic sub-
groups with calculated hazard ratio and its 95% confidence interval
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Figure 2  - Difference between SLOW-RISK (To) and SHIGH-RISK(To) as the function of 
the population survival rate for five pairs of (sensitivity, specificity)
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Figure 3  - Kaplan-Meier survival curves of the prognostic sub-groups for the 
simulated example with no censored data
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Figure 4  - Kaplan-Meier survival curves of the prognostic sub-groups for the 
simulated example with 30% censored data 
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Tables
Table 1  - A contingency table between positive and negative patients and 
predicted low-risk and high-risk patients
Table 2  - A confusion matrix between positive and negative patients and 
predicted low-risk and high-risk patients in the simulated example
Table 3  - Estimates of SLOW-RISK (5 years) and SHIGH-RISK (5 years) for the simulated 
example with no censored data taking into account various 5-year 
population survival rates
Table 4  - Estimates of SLOW-RISK (5 years) and SHIGH-RISK (5 years) for the simulated 
example with 30% censored data taking into account various 5-year 
population survival rates
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Table 5  - Estimates of the difference between SLOW-RISK (5 years) and SHIGH-RISK (5 
years) for various combinations of specificity, sensitivity and the 5-year 
population survival rate. Naive estimates which don't take into account 
the 5-year population survival rate are presented as well.
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